Welcome to CrystecPharma

CrystecPharma applies the latest supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.

Applications of our technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics.

Our solutions include the following:

  • Crystal and particle engineering
  • Stabilisation of therapeutic agents derived from biotechnology
  • Polymorph screening
  • Improved performance of poorly soluble drugs
  • Inhaled therapy
  • Taste masking
  • Crystallisation seeds
  • Residual solvent elimination


Latest News

Crystec’s Chief Scientist, Professor Peter York, has been invited to present at the 5th Medicon Valley Inhalation Symposium (MVIS)
August 5 2016

Professor Peter York, Crystec’s Chief Scientist, is looking forward to speaking at the upcoming MVIS conference in Lund, Sweden (12th-13th October 2016). The presentation will focus on 'Supercritical Fluid (SCF) Particle Engineering for Optimised Inhaled Delivery'.
Read More

Meet with Crystec at CPhI Worldwide 2016
July 15 2016

Crystec will be at CPhI Worldwide in Barcelona (4th – 6th October 2016). Contact Serena Wong (Serena.Wong@crystecpharma.com) to schedule a meeting at the event.
Read More

RSC Solid Form conference - Crystec’s Chief Scientist presents
March 16 2016

Professor Peter York presented at the recent RSC conference ‘Fundamentals of the Solid Form – New Insights and Developments’. For more information or for a copy of the slides please contact Serena Wong.
Read More